Mohs Micrographic Surgery and Surgical Excision for Nonmelanoma Skin Cancer Treatment in the Medicare Population

Authors:
  • MJMamta B. Jhaveri
    Mamta B. Jhaveri
  • PSPamela R. Soulos
    Pamela R. Soulos
  • RTRyan B. Turner
    Ryan B. Turner
  • WTWhitney L. Tolpinrud
    Whitney L. Tolpinrud
  • DDDaven Doshi
    Daven Doshi

Abstract
More than 3 million nonmelanoma skin cancers (NMSCs) are diagnosed annually in the United States; 1 in 5 Americans will develop skin cancer during their lifetime.1,2 The NMSC treatment options include electrodessication and curettage, cryosurgery, photodynamic therapy, laser therapy, radiation, medical therapy, surgical excision, and Mohs micrographic surgery (MMS).3 Surgical excision is effective for most primary basal cell carcinomas, but cure rates are higher with MMS in patients with recurrent, infiltrative, and high-risk anatomical site (face) cancers; MMS examines 100% of the surgical margin, which ensures definitive tumor removal and minimal loss of surrounding normal tissue.3,4

This publication has 14 references indexed in Scilit: